

BIOMARIN PHARMACEUTICAL INC  
Form 4  
March 11, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BIENAIME JEAN JACQUES**

2. Issuer Name and Ticker or Trading Symbol  
**BIOMARIN PHARMACEUTICAL INC [BMRN]**

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chief Executive Officer

(Last) (First) (Middle)  
  
C/O BIOMARIN  
PHARMACEUTICAL INC., 770  
LINDARO ST.  
  
(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
03/09/2015

SAN RAFAEL, CA 94901  
  
(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
			Code	V	Amount	Price	
Common Stock	03/09/2015	03/09/2015	M		15,000	A \$ 12.99	57,279 I Shares held by Bienaime Family Trust <sup>(1)</sup>
Common Stock	03/09/2015	03/09/2015	S		15,000	D \$ 112.1206 <sup>(2)</sup>	42,279 I Shares held by Bienaime Family Trust <sup>(1)</sup>

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock	03/09/2015	03/09/2015	S	4,000	D	\$ 112.1435 (3)	38,279	I	Shares held by Bienaime Family Trust (1)
Common Stock	03/10/2015	03/10/2015	S	2,021	D	\$ 114.894 (4)	36,258	I	Shares held by Bienaime Family Trust (1)
Common Stock							254,757	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy Common Stock)	\$ 12.99	03/09/2015	03/09/2015	M	15,000	11/11/2006(5)	05/10/2016	Common Stock	15,000
Stock Option (right to buy Common Stock)	\$ 12.99 (4)					11/11/2006(5)	05/10/2016	Common Stock	10,000
Stock Option (right to buy Common Stock)	\$ 12.99 (4)					11/11/2006(5)	05/10/2016	Common Stock	10,000

buy  
Common  
Stock)

Stock  
Option

(right to buy  
Common  
Stock) \$ 12.99  
(4)

11/11/2006<sup>(5)</sup> 05/10/2016

Common  
Stock

10,000

Common  
Stock)

Stock  
Option

(right to buy  
Common  
Stock) \$ 12.99  
(4)

11/11/2006<sup>(5)</sup> 05/10/2016

Common  
Stock

10,000

Common  
Stock)

Stock  
Option

(right to buy  
Common  
Stock) \$ 12.99  
(4)

11/11/2006<sup>(5)</sup> 05/10/2016

Common  
Stock

20,000

Common  
Stock)

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL, CA 94901	X		Chief Executive Officer	

## Signatures

/s/ Laura Randall Woodhead,  
Attorney-in-Fact 03/11/2015

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The reporting person and his spouse act as trustees for the Bienaime Family Trust

The price in column 4 is an average weighted price. The price actually received ranged from \$111.20 to \$113.75. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.

## Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

(3) The price in column 4 is an average weighted price. The price actually received ranged from \$111.32 to \$113.70. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.

(4) The price in column 4 is an average weighted price. The price actually received ranged from \$114.881 to \$114.95. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.

(5) Original option grant vests 6/48ths on November 11, 2006, and 1/48th on the 11th of every month thereafter.

(6) The reporting person's spouse is the trustee of each child's trust.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.